image of Drug Information Full Text (Two-Book Package)

Drug Information Full Text (Two-Book Package)

Request Information
  • Description
  • Details
  • Whats Included
Two premier pharmaceutical reference books in one: AHFS Drug Information and ASHP Injectable Drug Information. These books are available only as a two-book package; they are not sold separately.
AHFS Drug Information
2021 Edition

AHFS® DI® is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 94,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients.

AHFS is the only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization and the only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.

AHFS references are evidence-based and peer-reviewed, compiled without the influence of manufacturers, insurers, regulators, or other interested parties. No other drug information sources can make this claim.

AHFS DI contains information from medical literature and expert advice from over 500 medical scientists, physicians, pharmacists, pharmacologists, and other professionally qualified individuals that goes beyond FDA-approved labeling.

Monographs include: drug interactions; adverse reactions; cautions and toxicity; therapeutic perspective; specific dosage and administration information; preparations, chemistry, and stability; pharmacology and pharmacokinetics; contraindications; and more.

2021 Updates:

  • Drug information for COVID-19-related treatments, including use of antiviral agents such as remdesivir and lopinavir/ritonavir, SARS-CoV-2-specific monoclonal antibodies (e.g., bamlanivimab), as well as use of supporting agents such as corticosteroids, immune globulin, nitric oxide, and tocilizumab

  • Updated information on drugs commonly used for ICU sedation in critically ill patients with COVID-19, including propofol, dexmedetomidine, and midazolam and alternative drugs such as ketamine considered in potential drug shortage situations
  • Latest oncology therapies for the treatment of cancers associated with activating gene mutations and oncogenic gene fusions

    ASHP Injectable Drug Information
    Trissel, Lawrence A.
    21th Edition

    For more than 40 years ASHP has published the most trusted resource for injectable drug information. Our new ASHP® Injectable Drug InformationTM now delivers the same high-quality content that you can expect from ASHP with even MORE of the information you need to make decisive patient care decisions.

    This book is considered to be the gold standard for information on injectable drugs and it is widely used by pharmacists and other healthcare professionals across the world. With its 40+ year track record for covering vast amounts of data with precise, accurate detail, nothing else comes close for compatibility, stability, storage, and preparation of parenteral drugs.The 21st edition brings together, more than 360 monographs, information on injectable drugs available commercially in the United States and in other countries. The aim of this book has remained unchaged over four decades. Backed by quality, peer-reviewed published literature and authored under the editorial authority of ASHP, it is a must-have resource for every pharmacy.

    The 2021 edition features 18 new monographs and nearly 200 new references for a total of over 24,000 total compatibility pairs.

    As the industry’s “gold standard,” the 21st Edition is uniquely designed to make complex and thorough data easily accessible to busy practitioners worldwide.
  • Details
    Product Type:
    • Pharmacology
    • Pharmacy
    Update Frequency:
    • ASHP Injectable Drug Information

    Request Information

    Back To Top